A randomized clinical trial of valacyclovir in multiple sclerosis

Multiple Sclerosis

Volumn 11, Issue 3, 2005, Pages 286-295

  Friedman, Jacqueline E ^a,b,g   Zabriskie, J B ^b   Plank, C ^b   Ablashi, D ^c   Whitman, J ^c   Shahan, B ^d   Edgell, R ^e   Shieh, M ^b   Rapalino, O ^e   Zimmerman, R ^f   Sheng, D ^e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c Advanced Biotechnologies Inc   (United States)

^d GLAXOSMITHKLINE   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f WEILL CORNELL MEDICAL CENTER   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antiviral drugs; Clinical trials; Herpesvirus 6; Human antivirals; Multiple sclerosis (MS)

Indexed keywords

ANTIVIRUS AGENT; PLACEBO; VALACICLOVIR;

ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN HERPESVIRUS 6; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MANIA; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CYST; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

ACYCLOVIR; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DISABILITY EVALUATION; FEMALE; GAIT; HERPESVIRUS 6, HUMAN; HUMANS; IMMUNOGLOBULIN M; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PILOT PROJECTS; ROSEOLOVIRUS INFECTIONS; VALINE;

EID: 20144367519     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1185oa     Document Type: Article

References (26)

1. Compston A, Sadovnick AD. Epidemiology and genetics of multiple sclerosis. Curr Opin Neurol Neurosurg 1992; 5: 175-81.
2. Alvord EC Jr, Jahnke U, Fischer EH, Kies MW, Driscoll BF, Compston DA. The multiple causes of multiple sclerosis: the importance of age of infections in childhood. J Child Neurol 1987; 2: 313-21.
3. Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog Neurobiol 1995; 47: 425-48.
4. Dean G. The multiple sclerosis problem. Sci Am 1970; 223: 40-46.
5. Kurtzke JF, Hyllested K. Multiple sclerosis in the Faroe Islands. III. An alternative assessment of the three epidemics. Acta Neurol Scand 1987; 76: 317-39.
6. Banks T, Rouse B. Herpesviruses-immune escape artists? Clin Inf Dis 1992; 14: 933-41.
7. Herndon RM. Herpessviriuses in multiple sclerosis. Arch Neurol 1996; 53: 123-24.
8. Wandinger K, Jabs W, Siekhaus A, Bubel S, Trillenberg P, Wagner H et al. Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology 2000; 55: 178-84.
9. Ascherio A, Munger KL, Lennette ET, Spiegelman D, Hernán MA, Olek MJ et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 2001; 286: 3083-88.
10. Ferrante P, Mancuso R, Pagani E, Guerini FR, Calvo MG, Sarasella M et al. Molecular evidences for a role of HSV-1 in multiple sclerosis clinical acute attack. J Neurovirol 2000; 6 (Suppl 2): S109-14.
11. Challoner PB, Smith KT, Parker JD, Macleod DL, Coulter SN, Rose TM et al. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis. PNAS 1995; 92: 7440-44.
12. Yamanishi K, Okuno T, Shiraki, Takahashi M, Kondo T, Asano Y et al. Identification of human herpesvirus-6 as a causal agent for exanthem subitum. Lancet 1988; 1: 1065-67.
13. Friedman JE, Lyons MJ, Cu G, Ablashi DV, Whitman JE, Edgar M et al. The association of the human herpesvirus-6 and MS. Mult Scler 1999; 5: 355-62.
14. Sola P, Merelli E, Marasca R, Poggi M, Luppi M, Montorsi M et al. Human herpesvirus 6 and multiple sclerosis: survey of anti-HHV-6 antibodies by immunofluorescence analysis and of viral sequences by polymerase chain reaction. J Neurol, Neurosurg & Psych 1992; 56: 917-19.
15. Ablashi DV, Lapps W, Kaplan M, Whitman JE, Richert JR, Pearson GR. Human Herpesvirus-6 (HHV-6) infection in multiple sclerosis: a preliminary report. Multiple Sclerosis 1998; 4: 490-96.
16. Soldan SS, Berti R, Salem N, Secchiero P, Flamand L, Calabresi PA et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nature Med 1997; 12: 1394-97.
17. Pellett PE, Sanchez-Martinez D, Dominguez G, Black JB, Anton E, Greenmoyer C et al. A strongly immunoreactive virion protein of human herpesvirus 6 variant B strain Z29: identification and characterization of the gene and mapping of a variant-specific monoclonal antibody reactive epitope. Virol 1993; 195: 521-31.
18. Sanders VJ, Felisan S, Waddell A, Tourtellotte WW. Detection of herpesviridae in postmortem multiple sclerosis brain tissue and controls by polymerase chain reaction. J Neurovirol 1966; 2: 249-58.
19. Novoa LJ, Nagra RM, Nakawatase T, Edwards-Lee T, Tourtellotte WW, Cornford ME. Fulminant demyelinating encephalomyelitis associated with productive HHV-6 infection in an immunocompetent adult. J Med Virol 1997; 52: 301-308.
20. Bech E, Lycke J, Gadeberg P, Hansen HJ, Malmestrom C, Andersen O et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology 2002; 58: 31-36.
21. Lycke J, Svennerholm B, Hjelmquist E, Frisen L, Badr G, Andersson M et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. J Neurol 1996; 243: 214-24.
22. Martin C, Enbom M, Soderstrom M, Fredrikson S, Dahl H, Lycke J et al. Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis. Acta Neurol Scand 1997; 95: 280-83.
23. Enbom M, Wang FZ, Fredrikson S, Martin C, Dahl H, Linde A. Similar humoral and cellular immunological reactivities to human herpesvirus 6 in patients with multiple sclerosis and controls. Clin Diag Lab Immunol 1999; 6: 545-49.
24. Readon JE, Spector T. Acyclovir. Mechanism of antiviral action and potentiation by ribonucleotide reductase inhibitors. Adv Pharmacol 1991; 22: 1-27.
25. Littler E, Stuart AD, Chee MS. Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir. Nature 1992; 358: 160-62.
26. Wagstaff AJ, Faulds D, Goa KL. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47: 153-205.